Primer on Medical Genomics Part XII: Pharmacogenomics -- General Principles With Cancer as a Model

Goetz, Matthew P.; Ames, Matthew M.; Weinshilboum, Richard M.
March 2004
Mayo Clinic Proceedings;Mar2004, Vol. 79 Issue 3, p376
Academic Journal
The Human Genome Project has resulted in a new era in the field of pharmacogenetics in which researchers are rapidly discovering new genetic variation, which may help to explain interindividual variability in drug efficacy and toxicity. Pharmacogenetics is the study of the role of genetic inheritance in individual variation in drug response and toxicity. With the convergence of advances in pharmacogenetics and human genomics, the field of pharmacogenomics has emerged during the past decade. Pharmacogenomics is used to refer to the study of the relationship between specific DNA-sequence variation and drug effect. In few other disciplines of medicine are the clinical examples of pharmacogenetics more striking than in oncology. In this field, treatment of patients with cancer is accomplished primarily through the use of chemotherapeutic drugs that have narrow therapeutic indexes, ie, the difference between the toxic and therapeutic dose is relatively small. In this review, we discuss several selected, clinically relevant examples of ways in which sequence variation in genes that encode drug enzymes, transporters, and drug targets can alter the efficacy and/or adverse-effect profile of "standard" doses of chemotherapeutic drugs. Additionally, we discuss some of the ways in which physicians are currently applying this knowledge in the treatment of patients with cancer.


Related Articles

  • In Silico Drug Discovery: Solving the “Target-rich and Lead-poor” Imbalance Using the Genome-to-drug-lead Paradigm. Pang, Y. P. // Clinical Pharmacology & Therapeutics;Jan2007, Vol. 81 Issue 1, p30 

    Advances in genomics, proteomics, and structural genomics have identified a large number of protein targets. Virtual screening has gained popularity in identifying drug leads by computationally screening large numbers of chemicals against experimentally determined protein targets. In that...

  • Validating cancer drug targets. Benson, John D.; Chen, Ying-Nan P.; Cornell-Kennon, Susan A.; Dorsch, Marion; Sunkyu im; Leszczyniecka, Magdalena; Sellers, William R.; Lengauer, Christoph // Nature;5/25/2006, Vol. 441 Issue 7092, p451 

    A cancer drug target is only truly validated by demonstrating that a given therapeutic agent is clinically effective and acts through the target against which it was designed. Nevertheless, it is desirable to declare an early-stage drug target as ‘validated’ before investing in a...

  • Novel Molecular Targets in Cancer Chemotherapy Waiting for Discovery. Kunick, Conrad // Current Medicinal Chemistry - Anti-Cancer Agents;Sep2004, Vol. 4 Issue 5, p421 

    Despite a number of advances in the past decades the medicinal cancer therapy is hampered by problems of severe unwanted side effects and the development of resistances. Many established anti-cancer drugs are directed toward targets that are not specific for cancer but are essential biochemical...

  • Therapy: Special delivery. McCarthy, Nicola // Nature Reviews Cancer;Aug2009, Vol. 9 Issue 8, p534 

    The article offers information on the research that could reduce cancer therapy side effects by specifically targeting drugs to the tumor. According to researchers in Great Britain, the utilization of tumor-targeted minicells could achieve such objective. Research results indicated that...

  • Optimizing Liposomal Cisplatin Efficacy through Membrane Composition Manipulations. Zisman, Natalia; Santos, Nancy Dos; Johnstone, Sharon; Tsang, Alan; Bermudes, David; Mayer, Lawrence; Tardi, Paul // Chemotherapy Research & Practice;2011, p1 

    The first liposomal formulation of cisplatin to be evaluated clinically was SPI-077. Although the formulation demonstrated enhanced cisplatin tumor accumulation in preclinical models it did not enhance clinical efficacy, possibly due to limited cisplatin release from the formulation localized...

  • Particle Size Determination in Pharmaceutical Applications.  // LabAsia;2011, Vol. 18 Issue 1, p22 

    The article focuses on the importance of the particle size of dosage forms in the efficacy of the drug.

  • News Blast.  // Bio-IT World;Mar2005, Vol. 4 Issue 3, p18 

    Presents news briefs on biotechnology research in the U.S. as of March 2005. Plan of the International HapMap Consortium to create a map of human genetic variation; Benefit of Revlimid drug to patients suffering from myelodysplastic syndrome; Potential of blood protein molecules, artemisinin...

  • Multicenter Phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma. Sugiura, Hideshi; Fujiwara, Yasuhiro; Ando, Masashi; Kawai, Akira; Ogose, Akira; Ozaki, Toshifumi; Yokoyama, Ryohei; Hiruma, Toru; Ishii, Takeshi; Morioka, Hideo; Mugishima, Hideo // Journal of Orthopaedic Science;Sep2010, Vol. 15 Issue 5, p654 

    Background: Imatinib myselate is a molecularly targeted drug that inhibits Abl tyrosine kinase, as well as type III tyrosine kinase receptors such as platelet-derived growth factor receptor (PDGFR), KIT, colony-stimulating factor 1 receptor (CSF-1R), and discoidin domain receptor (DDR). Ph1...

  • A Phase II Study of a Daily x 4 Schedule of Vinorelbine Plus Cisplatin for Advanced Non-small Cell Lung Cancer. Han, Ji-Youn; Kim, Ki Won; Kim, Jung Ah; Kang, Jin Hyung; Jin, Jong-Youl; Hong, Young Seon; Park, Suk Young; Song, Jung-Sup; Park, Jong Won; Kim, Hoon-Kyo; Lee, Kyung Shik; Choi, Byung Gil // Japanese Journal of Clinical Oncology;Oct2000, Vol. 30 Issue 10 

    Explores the possibility of increasing the dose of advanced non-small cell lung cancer drug, vinorelbine on a four times daily schedule to determine whether dose intensity affects response to the drug. Overall response rate; Toxicity of myelosuppression; Comparable therapeutic activity of the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics